Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

July 30, 2018

Primary Completion Date

April 3, 2025

Study Completion Date

July 17, 2025

Conditions
Ulcerative ColitisCrohn's Disease
Interventions
DRUG

Vedolizumab

Vedolizumab intravenous infusion

Trial Locations (23)

3526

BAZ Megyei Korhaz es Egyetemi Oktatokorhaz, Miskolc

4032

Debreceni Egyetem Klinikai Kozpont, Debrecen

6720

Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont, Szeged

10031

Columbia University Medical Center, New York

30342

Children's Center for Digestive Healthcare, Atlanta

32207

Nemours Childrens Specialty Care - Jacksonville, Jacksonville

52621

The Edmond and Lily Safra Children's Hospital - Sheba Medical Center, Ramat Gan

61093

Kharkiv Regional Clinical Children's Hospital, Kharkiv

75015

Hopital Necker-Enfants Malades, Paris

77030

Texas Children's Hospital, Houston

90048

Cedars-Sinai Medical Center, Los Angeles

92868

Children's Hospital of Orange County, Orange

94158

University of California San Francisco, San Francisco

98105

Seattle Children's Hospital, Seattle

3436212

Carmel Medical Center, Haifa

4920235

Schneider Children's Medical Center of Israel, Petach Tiqwa

6423906

Tel Aviv Sourasky Medical Center, Tel Aviv

9103102

Shaare Zedek Medical Center, Jerusalem

06106-3322

Connecticut Children's Medical Center, Hartford

30-663

Uniwersytecki Szpital Dzieciecy w Krakowie, Krakow

35-302

Gabinet Lekarski Dr. Hab. N. Med. Bartosz Korczowski, Rzeszów

91-738

Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi Osrodek Pediatryczny im Marii Konopnic, Lodz

E1 1BB

Barts and The London NHS Trust, London

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Takeda Development Center Americas, Inc.

INDUSTRY

lead

Takeda

INDUSTRY